Pleural decortication and hyperthermic intrathoracic chemotherapy for pseudomyxoma

References

• Mittal R, Chandramohan A, Moran B. Pseudomyxoma peritonei: natural history and treatment. Int J Hyperth. 2017;33(5):511–519.
   PubMed Web of Science ®Google Scholar
• Doyle MP, Villanueva CI, Davies MP, et al. Cytoreductive surgery and heated intrathoracic chemotherapy for thoracic extension of pseudomyxoma peritonei. Integr Cancer Sci Therap. 2016;3(4):504–508.
   Google Scholar
• Ghosh RK, Somasundaram M, Ravakhah K, et al. Pseudomyxoma peritonei with intrathoracic extension: a rare disease with rarer presentation from low-grade mucinous adenocarcinoma of the appendix. BMJ Case Rep. 2016;2016:bcr2015211076.
   PubMedGoogle Scholar
• Chua TC, Yan TD, Yap ZL, et al. Thoracic cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy for pseudomyxoma peritonei. J Surg Oncol. 2009;99(5):292–295.
   PubMed Web of Science ®Google Scholar
• Geisinger KR, Levine EA, Shen P, et al. Pleuropulmonary involvement in pseudomyxoma peritonei: morphologic assessment and literature review. Am J Clin Pathol. 2007;127(1):135–143.
   PubMed Web of Science ®Google Scholar
• Pestieau SR, Esquivel J, Sugarbaker PH. Pleural extension of mucinous tumor in patients with pseudomyxoma peritonei syndrome. Ann Surg Oncol. 2000;7(3):199–203.
   PubMed Web of Science ®Google Scholar
• Pestieau SR, Wolk R, Sugarbaker PH. Congenital pleuroperitoneal communication in a patient with pseudomyxoma peritonei. J Surg Oncol. 2000;73(3):174–178.
   PubMed Web of Science ®Google Scholar
• Senthil M, Harrison LE. Simultaneous bicavitary hyperthermic chemoperfusion in the management of pseudomyxoma peritonei with synchronous pleural extension. Arch Surg. 2009;144(10):970–972.
   PubMedGoogle Scholar
• Cao C, Tian D, Park J, et al. A systematic review and Meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer. 2014;83(2):240–245.
   PubMed Web of Science ®Google Scholar
• Taioli E, Wolf AS, Flores RM. Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma. Ann Thorac Surg. 2015;99(2):472–480.
   PubMed Web of Science ®Google Scholar
• Bovolato P, Casadio C, Billè A, et al. Does surgery improve survival of patients with malignant pleural mesothelioma: a multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol. 2014;9(3):390–396.
   PubMed Web of Science ®Google Scholar
• Migliore M, Ried M, Molins L, et al. Hyperthermic intrathoracic chemotherapy (HITHOC) should be included in the guidelines for malignant pleural mesothelioma. Ann Transl Med. 2021;9(11):960–960.
   PubMed Web of Science ®Google Scholar
• Migliore M, Combellack T, Williams J, et al. Hyperthermic intrathoracic chemotherapy in thoracic surgical oncology: future challenges of an exciting procedure. Futur Oncol. 2021;17(30):3901–3904.
   PubMed Web of Science ®Google Scholar
• Dawson A, Kutywayo K, Mohammed SB, et al. Cytoreductive surgery with hyperthermic intrathoracic chemotherapy for malignant pleural mesothelioma: a systematic review. Thorax. 2022;thoraxjnl-2021-218214.
   Web of Science ®Google Scholar
• Alzahrani N, Ferguson JS, Valle SJ, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: long-term results at St george hospital, Australia. ANZ J Surg. 2016;86(11):937–941.
   PubMed Web of Science ®Google Scholar
• Baratti D, Kusamura S, Nonaka D, et al. Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2009;249(2):243–249.
   PubMed Web of Science ®Google Scholar
• Vaira M, Cioppa T, Marco D, et al. Management of pseudomyxoma peritonei by cytoreduction + HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience. In Vivo. 2009;23(4):639–644.
   PubMed Web of Science ®Google Scholar
• Zhao ZY, Zhao SS, Ren M, et al. Effect of hyperthermic intrathoracic chemotherapy on the malignant pleural mesothelioma: a systematic review and metaanalysis. Oncotarget. 2017;8(59):100640–100647.
   PubMedGoogle Scholar
• Järvinen T, Paajanen J, Ilonen I, et al. Hyperthermic intrathoracic chemoperfusion for malignant pleural mesothelioma: systematic review and Meta-analysis. Cancers (Basel). 2021;13(14):3637.
   PubMed Web of Science ®Google Scholar
• Zhou H, Wu W, Tang X, et al. Effect of hyperthermic intrathoracic chemotherapy (HITHOC) on the malignant pleural effusion. Medicine (Baltimore). 2017;96(1):e5532.
   PubMed Web of Science ®Google Scholar
• Ashraf-Kashani N, Bell J. Haemodynamic changes during hyperthermic intra-thoracic chemotherapy for pseudomyxoma peritonei. Int J Hyperthermia. 2017;33(6):675–678.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Chang D, Stuart OA. Hyperthermic intraoperative thoracoabdominal chemotherapy. Gastroenterol Res Pract. 2012;2012:1–7.
   Web of Science ®Google Scholar
• Chen CF, Huang CJ, Kang WY, et al. Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin/fluorouracil/leucovorin (FOLFOX4). World J Surg Oncol. 2008;6:118.
   PubMed Web of Science ®Google Scholar
• Wisselink DD, Braakhuis LLF, Gallo G, et al. Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer. Crit Rev Oncol Hematol. 2019;142:119–129.
   PubMed Web of Science ®Google Scholar
• Sgarbura O, Al Hosni M, Petruzziello A, et al. Complete pathologic response after two-stage cytoreductive surgery with HIPEC for bulky pseudomyxoma peritonei: proof of concept. Int J Hyperthermia. 2020;37(1):585–591.
   PubMed Web of Science ®Google Scholar
• Elias D, Bonnay M, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13(2):267–272.
   PubMed Web of Science ®Google Scholar
• Elias D, Laurent S, Antoun S, et al. Pseudomyxoma peritonei treated with complete resection and immediate intraperitoneal chemotherapy. Gastroenterol Clin Biol. 2003;27(4):407–412.
   PubMedGoogle Scholar
• Marcotte E, Dubé P, Drolet P, et al. Hyperthermic intraperitoneal chemotherapy with oxaliplatin as treatment for peritoneal carcinomatosis arising from the appendix and pseudomyxoma peritonei: a survival analysis. World J Surg Onc. 2014;12(1):332.
   PubMed Web of Science ®Google Scholar
• Marcotte E, Sideris L, Drolet P, et al. Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from appendix: preliminary results of a survival analysis. Ann Surg Oncol. 2008;15(10):2701–2708.
   PubMed Web of Science ®Google Scholar
• Piché N, Leblond FA, Sidéris L, et al. Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis: a study of the effect of heat on intraperitoneal oxaliplatin using a murine model. Ann Surg. 2011;254(1):138–144.
   PubMed Web of Science ®Google Scholar
• Kocsis A, Markóczy Z, Agócs L, et al. [Pseudomyxoma of the pleura and of the peritoneum – case report of a rare disease]. Magy Seb. 2012;65(1):24–26.
   PubMedGoogle Scholar